UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of Registrant as specified in its charter) Ohio (State or other jurisdiction of incorporation or or ...

Westlake, Ohio-based Nordson Corporation (NDSN) engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids. Valued at $13.2 billion by market cap, the company's products include customized electronic controls for the precise application and curing of materials to meet customers' requirements. Companies worth $10 billion or more are typically classified as “large-cap stocks,” and NDSN fits the label perf ...

Core Insights - Nordson Corporation is a global leader in precision technology solutions, specializing in equipment for dispensing adhesives, coatings, sealants, and biomaterials [1] - D.A. Davidson has set a price target of $290 for Nordson's stock, indicating a potential upside of 23.29% from its current trading price of $235.21 [1][5] Financial Performance - For the fiscal fourth quarter ending October 31, 2025, Nordson reported sales of $752 million, reflecting a 1% increase from $744 million in the previous year [2][5] - The sales growth was supported by a favorable currency translation of 2% and a 1% contribution from acquisitions, although it was partially offset by a divestiture in the medical contract manufacturing segment and a 1% decrease in organic sales [2] Stock Performance - The current stock price of Nordson is $234.35, showing a slight decrease of approximately 0.03% from the previous trading session [3] - Over the past year, the stock has experienced significant volatility, reaching a high of $251.47 and a low of $165.03, with a market capitalization of approximately $13.17 billion [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Nordson Corporation's adjusted earnings for Q4 fiscal 2025 were $3.03 per share, exceeding the Zacks Consensus Estimate of $2.93, marking a 9% year-over-year increase [1] - Revenues for the quarter were $751.8 million, a 1% increase from the previous year, but below the consensus estimate of $769 million [2][9] - The company reported improved margins, with gross profit rising 5.1% year over year and gross margin increasing by 220 basis points to 56.3% [6][9] Quarterly Results of NDSN - Revenue breakdown showed a 4.4% decline in the Asia Pacific region to $225.5 million, while Europe saw a 5.4% increase to $195.3 million, and the Americas grew by 2.4% to $331 million [3] - Industrial Precision Solutions generated $361.7 million, down 1.5% year over year, contributing 48% to total revenues [3] - Medical and Fluid Solutions revenues were $219.5 million, up 9.6% year over year, with organic sales increasing by 7.4% [4] - Advanced Technology Solutions reported $170.6 million, down 3.6% year over year, with organic sales decreasing by 4.9% [5] Margin Profile - Cost of sales decreased by 3.9% to $328.4 million, leading to a gross profit of $423.5 million [6] - Selling and administrative expenses fell by 7% to $208.9 million, while adjusted EBITDA rose 6.1% to $255.7 million, with an operating margin of 28.5% [7] Balance Sheet & Cash Flow - At the end of Q4 fiscal 2025, cash and cash equivalents were $108.4 million, down from $116 million at the end of fiscal 2024, while long-term debt decreased to $1.68 billion from $2.10 billion [10] - The company generated net cash of $719.2 million from operating activities, a 29.3% increase year over year [11] Dividends/Share Buyback - Nordson paid out $179.1 million in dividends, an 11% increase from the previous year, and repurchased shares worth $306.4 million, significantly up from $33.3 million [12] Outlook - For fiscal 2026, Nordson projects sales between $2.83 billion and $2.95 billion, with adjusted earnings expected to be between $10.80 and $11.50 per share [13]

Nordson (NasdaqGS:NDSN) Q4 2025 Earnings Call December 11, 2025 08:30 AM ET Company ParticipantsLara Mahoney - VP of Investor RelationsSundaram Nagarajan - CEODaniel Hopgood - CFOConference Call ParticipantsWalter Liptak - AnalystChris Glynn - AnalystRobert Jamieson - AnalystMatt Summerville - AnalystAndrew Buscaglia - AnalystBrad Hewitt - AnalystMitch Moore - AnalystMike Halloran - AnalystOperatorLadies and gentlemen, thank you for joining us, and welcome to the Nordson Corporation Fourth Quarter and Fisca ...

Financial Data and Key Metrics Changes - Sales for Q4 2025 were $752 million, up 1% from $744 million in Q4 2024, with organic sales decreasing by 1% [10] - Full year sales reached a record $2.8 billion, an increase of 4% year-over-year, with adjusted earnings per share growing 9% to $3.03 in Q4 [5][18] - EBITDA for Q4 was $256 million, representing a 34% margin, and full year EBITDA was $900 million, or 32% of sales [5][19] Business Line Data and Key Metrics Changes - Industrial Precision Solutions (IPS) sales decreased 2% to $362 million, with organic sales down nearly 4% [14] - Medical and Fluid Solutions sales increased 10% to $220 million, with organic sales up 7% [15] - Advanced Technology Solutions (ATS) sales decreased 4% to $171 million, with organic sales down approximately 5% [17] Market Data and Key Metrics Changes - The company reported a 5% increase in backlog year-over-year, with approximately $600 million in backlog entering fiscal 2026 [27] - Currency translation positively impacted sales by 2% in Q4 2025 [10] Company Strategy and Development Direction - The Ascend strategy has been pivotal in achieving record sales and EBITDA, with a focus on operational excellence and strategic M&A [7][19] - The company aims for average annual revenue growth of 6%-8% and adjusted EPS growth of 10%-12% from 2025 to 2029 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges and highlighted strong demand in core markets, particularly in medical and semiconductor applications [25][26] - The company anticipates returning to normal growth rates in IPS and mid-single digit organic growth in medical [25][26] Other Important Information - The company generated record cash flow of $194 million in Q4, with a cash conversion rate of 128% [5] - Share repurchases totaled approximately $300 million, and dividends were increased for the 62nd consecutive year [9][22] Q&A Session Summary Question: Insights on ATS segment and semiconductor applications - Management noted that strength remains in semiconductor applications, particularly for AI and cloud computing, while automotive demand is stabilizing [33] Question: Margin trajectory for 2026 - Management indicated that margins in IPS and ATS are expected to be sustainable, while medical margins may stabilize in the upper 30% range [34] Question: Polymer processing outlook - Management expects improvement in polymer processing order entry and backlog, indicating that the segment has troughed [40] Question: X-ray inspection business performance - Management highlighted that X-ray inspection has solid exposure to both semiconductor and automotive markets, with new product launches expected to drive growth [50] Question: M&A strategy and stock buyback - Management confirmed a robust M&A pipeline while balancing share repurchases, emphasizing the importance of strategic and financial discipline [54][56] Question: Guidance rationale and market sensitivity - Management explained that guidance reflects a range of potential outcomes, planning for both upside and downside scenarios [62]

Financial Data and Key Metrics Changes - Sales for Q4 2025 were $752 million, up 1% from $744 million in Q4 2024, with organic sales decreasing by 1% [10] - Adjusted earnings per share grew 9% year-over-year to $3.03, exceeding the midpoint of quarterly guidance [12] - Full year sales reached a record $2.8 billion, up 4% from the previous year, with adjusted diluted earnings per share of $10.24, also up 5% [18][19] Business Line Data and Key Metrics Changes - Industrial Precision Solutions (IPS) sales decreased 2% to $362 million, with organic sales down nearly 4% [13] - Medical and Fluid Solutions sales increased 10% to $220 million, with organic sales volume up 7% [14] - Advanced Technology Solutions (ATS) sales decreased 4% to $171 million, with organic sales down approximately 5% [17] Market Data and Key Metrics Changes - The company reported a 5% year-over-year increase in backlog, reaching approximately $600 million [26] - Currency translation positively impacted sales by 2% during the quarter [10] - The company noted stabilization in demand for automotive and polymer processing end markets [24] Company Strategy and Development Direction - The Ascend strategy has been pivotal in achieving record sales and EBITDA, with a focus on operational excellence and strategic M&A [6][8] - The company aims for average annual revenue growth of 6%-8% and adjusted EPS growth of 10%-12% from 2025 to 2029 [23] - The company is positioned to capitalize on profitable growth opportunities as key market headwinds have subsided [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to convert market opportunities into bottom-line results, anticipating a strong start to fiscal 2026 [22][26] - The company highlighted that customer destocking in the medical segment is behind them, with expectations for mid-single-digit organic growth [24] - Management acknowledged the importance of planning for both upside and downside scenarios in guidance, reflecting a cautious yet optimistic outlook [44][45] Other Important Information - The company generated record cash flow of $194 million in Q4, with a conversion rate of 128% to net income [5] - Free cash flow for the full year was a record $661 million, enabling share repurchases and dividend increases [21] - The company ended the year with a leverage ratio of 2.1 times, near the low end of its targeted range [20] Q&A Session Summary Question: Insights on ATS segment and semiconductor applications - Management noted that strength remains concentrated in semiconductor applications for AI and cloud computing, with automotive stabilizing [29][30] Question: Margin trajectory for 2026 - Management indicated that margins in IPS and ATS are expected to be sustainable, with upper 30s% margins in the medical segment being achievable [31][32] Question: Polymer processing outlook - Management stated that polymer processing has troughed, with expectations for improvement in order entry and backlog [33][52] Question: Guidance rationale - Management explained that guidance reflects a range of potential outcomes, planning for both upside and downside scenarios [44][45] Question: Backlog trends - Management confirmed that backlog is down sequentially, which is typical for Q1, but up 5% year-over-year [55]

Group 1 - The article does not provide any specific content related to a company or industry [1]

4Q & FY Fiscal 2025 Webcast Agenda December 11, 2025 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative ...